A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Latest Information Update: 04 May 2020
At a glance
- Drugs Paricalcitol (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 16 Apr 2019 Status changed from active, no longer recruiting to completed.
- 23 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2014 New trial record